What Longboard Pharmaceuticals, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Lind Kevin Robert | President and CEO | Dec 02 | Tender Offer · U | −363,740 | $60.00 | −$21.8M | 0 |
| Kaye Randall | Executive Vice President & CMO | Dec 02 | Tender Offer · U | −30,554 | $60.00 | −$1.83M | 0 |
| Kaye Randall | CMO | Nov 19 | Exercise / conversion · M | +30,554 | $6.00 | +$183K | 48,474 |
| Lind Kevin Robert | CEO | Nov 13 | Gift · G | −80,000 | — | — | 363,740 |
| Lind Kevin Robert | CEO | Nov 13 | Exercise / conversion · M | +12,808 | $3.12 | +$40K | 443,740 |
| Kaye Randall | CMO | Oct 15 | Disclosed 10b5-1 sale · S | −16,667 | $59.04 | −$984K | 17,920 |
| Kaye Randall | CMO | Oct 15 | Exercise / conversion · M | +16,667 | $4.35 | +$72.5K | 34,587 |
| Kaye Randall | CMO | Sep 16 | Disclosed 10b5-1 sale · S | −1,900 | $34.04 | −$64.7K | 17,920 |
| Kaye Randall | CMO | Sep 16 | Disclosed 10b5-1 sale · S | −1,200 | $33.12 | −$39.7K | 19,820 |
| Kaye Randall | CMO | Sep 16 | Disclosed 10b5-1 sale · S | −4,200 | $31.81 | −$134K | 21,020 |
| Kaye Randall | CMO | Sep 16 | Disclosed 10b5-1 sale · S | −9,366 | $30.89 | −$289K | 25,220 |
| Kaye Randall | CMO | Sep 16 | Exercise / conversion · M | +16,666 | $4.35 | +$72.5K | 34,586 |
| Lind Kevin Robert | CEO | Aug 12 | Exercise / conversion · M | +2,217 | $4.20 | +$9.31K | 430,932 |
| Lind Kevin Robert | CEO | Aug 12 | Exercise / conversion · M | +80,265 | $3.12 | +$251K | 428,715 |
| Kaye Randall | CMO | Aug 12 | Open-market sale · S | −6,191 | $35.03 | −$217K | 17,920 |
| Kaye Randall | CMO | Aug 12 | Open-market sale · S | −10,476 | $34.55 | −$362K | 24,111 |
| Kaye Randall | CMO | Aug 12 | Exercise / conversion · M | +16,667 | $4.35 | +$72.5K | 34,587 |
| Kaye Randall | CMO | Jun 25 | Open-market sale · S | −100 | $20.87 | −$2.09K | 0 |
| Roberts Brandi | CFO | Feb 08 | Grant / award · A | +15,090 | — | — | 15,090 |
| Kaye Randall | CMO | Feb 08 | Grant / award · A | +17,920 | — | — | 17,920 |
Loading...